The executive order President Trump signed on April 18, 2026, directs federal agencies to speed up research and potential FDA approval for psychedelic compounds including ibogaine, psilocybin, LSD, MDMA, and ketamine. For people living with treatment-resistant PTSD, depression, or substance use disorders, this is a concrete policy shift.
But a policy announcement is not the same as a treatment you can access tomorrow. Some of these compounds are years away from FDA approval. Ketamine is already available under medical supervision. Understanding that difference matters if you or someone you care about is weighing options right now.
What the executive order actually does
The executive order includes several concrete directives. According to NPR’s reporting, President Trump directed the FDA to fast-track review of psychedelics like psilocybin and ibogaine, and ordered $50 million in federal funds to support state programs developing psychedelic therapies for serious mental illness.
The order also instructs the FDA and DEA to create a pathway for eligible patients to access investigational psychedelic drugs under the Right to Try Act, originally signed into law in 2018. That law allows people with life-threatening conditions and limited treatment options to use drugs that have completed Phase 1 clinical trials but lack full FDA approval.
According to Bloomberg Law, the FDA will issue national priority vouchers for three psychedelic compounds, which FDA Commissioner Mary Makary said could compress review timelines from months to weeks. The agency is also clearing the way for the first human ibogaine trials conducted on U.S. soil.
Which psychedelics are named, and where they stand
The executive order names several compounds. Their regulatory status and evidence bases vary widely.
Ibogaine is a plant-derived compound currently classified as a Schedule I substance, a category the DEA defines as having “no currently accepted medical use and a high potential for abuse.” It has drawn particular attention for its potential to reduce PTSD symptoms and traumatic brain injury effects in veterans. A 2024 Stanford Medicine study published in Nature Medicine found that 30 Special Operations veterans who received ibogaine with intravenous magnesium showed significant improvements in functioning, PTSD, depression, and anxiety, with no serious cardiac events. A follow-up study published in Nature Mental Health in 2025 from the same Stanford team found improvements in brain function associated with cognitive flexibility.
These results are encouraging, but context matters. Both studies involved only 30 participants and had no placebo group. Ibogaine carries documented cardiac risks: it can trigger dangerous heart rhythms and has been linked to more than 30 deaths in the medical literature, according to the Multidisciplinary Association for Psychedelic Studies (MAPS). Most of those events occurred in unregulated settings without adequate cardiac screening.
Psilocybin, the active ingredient in “magic mushrooms,” is also Schedule I. Two states, Oregon and Colorado, have legalized psilocybin therapy, and Phase III clinical trials are underway for treatment-resistant depression. The FDA has granted psilocybin “breakthrough therapy” designation based on early results. A meta-analysis of nine clinical trials (596 participants) found a large antidepressant effect, with 57% of psilocybin participants meeting response criteria compared to 22% in the control group, and remission rates of 45% versus 14%. A separate Phase II trial found that psilocybin performed comparably to the SSRI escitalopram over six weeks, with secondary outcomes favoring psilocybin. It is not yet FDA-approved for any psychiatric condition, but the clinical data so far is among the strongest in the psychedelic research field.
MDMA received “breakthrough therapy” designation from the FDA in 2017 for the treatment of PTSD. Two Phase 3 trials produced striking results: in the second confirmatory trial, published in Nature Medicine in 2023, 71.2% of participants receiving MDMA-assisted therapy no longer met diagnostic criteria for PTSD by the end of the 18-week study period, compared to 47.6% in the placebo group. An earlier Phase II study reported an 80% remission rate sustained at three years after just two or three sessions. Despite these results, the FDA declined approval in 2024, citing concerns about trial methodology. The regulatory path forward remains unclear, but the clinical evidence for MDMA-assisted therapy in PTSD is substantial and has energized the broader movement toward psychedelic-assisted treatments.
Ketamine stands apart from these compounds in one important way: it is already legal and available. Ketamine is a Schedule III substance, which means licensed clinicians can prescribe it today. The FDA originally approved ketamine as an anesthetic in 1970, and it has been on the World Health Organization’s List of Essential Medicines since 1985. When prescribed for depression, anxiety, or PTSD, it is used off-label, a standard and legally accepted practice across medicine.
Esketamine, marketed as Spravato, is the only FDA-approved psychedelic-related treatment for a psychiatric condition: treatment-resistant depression and major depressive disorder with suicidal ideation. Nushama is a certified Spravato provider and administers it regularly in our clinic, so our clinical team has deep, firsthand experience with how this treatment works in practice and which patients benefit most from it.
Why this matters for veterans and people with treatment-resistant conditions
The executive order focuses heavily on veterans. According to the White House, more than 14 million American adults have a serious mental illness. The Military.com coverage of the order notes that an estimated 18 veterans die by suicide each day, and conventional PTSD treatments leave a significant number without meaningful relief.
Tom Feegel, CEO of Beond, told Military.com the order represents “a meaningful turning point in how our nation approaches brain health within the military community, particularly for veterans navigating treatment-resistant PTSD, traumatic brain injury, depression, and substance use disorders.”
Nushama’s CEO Jay Godfrey was also quoted in the same article: “At Nushama, our focus is on delivering care safely and ethically in alignment with evolving evidence and regulatory requirements. We’re investing in experienced clinical teams, appropriate facilities and patient-safety protocols to support responsible translation from research to practice where permitted.”
The bipartisan support for this order reflects a growing acknowledgment that the standard treatment toolkit for conditions like PTSD and treatment-resistant depression is insufficient for many people. When conventional approaches have not worked, the question becomes what options are available, safe, and backed by evidence.
Ketamine is the psychedelic therapy you can access today
While ibogaine and psilocybin may be years from FDA approval, ketamine-assisted therapy is available right now.
IV ketamine (intravenous ketamine) works through NMDA receptor pathways, a mechanism distinct from traditional antidepressants that target serotonin. This promotes neuroplasticity, the brain’s ability to form new neural connections. Symptom improvement can be noticeable within hours or days, rather than the weeks or months typical of traditional medications.
The evidence base for ketamine continues to grow. A 2025 study published in the Journal of Psychopharmacology, “Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm” by Henry A. MacConnel, Mitch Earleywine, and Steven Radowitz, tracked 117 outpatients with treatment-resistant PTSD who received IV ketamine in a supportive, psychedelic-paradigm environment. The results: 75% of participants experienced clinically meaningful improvement, and over 61% achieved remission. These outcomes exceed what most infusion-only models report, and they point to something worth noting: how and where ketamine is administered appears to matter as much as the medicine itself.
That finding aligns with a core principle of psychedelic-assisted therapy. The medicine is one part of the equation. Preparation and integration, the work before and after each session to process and apply insights, are what help translate acute symptom relief into lasting change.
What safe psychedelic-assisted therapy actually requires
The executive order calls for FDA protocols around “safe therapeutic use” of psychedelics. This deserves close attention, because the safety infrastructure around any psychedelic therapy is what separates a promising compound from a responsible treatment.
For ibogaine, the central concern is cardiac. It can cause dangerous heart rhythms, and the clinics where Americans currently receive it, mostly in Mexico and the Caribbean, operate without U.S. regulatory oversight. There is no standardized screening, no required monitoring, and no obligation to report adverse events.
For IV ketamine, the safety framework is well established when delivered in a clinical setting. At Nushama, every IV ketamine session includes:
- A comprehensive medical and psychiatric screening before treatment begins
- Continuous vital-sign monitoring throughout each session, with blood pressure, heart rate, and oxygen saturation checked every 10 minutes
- Individually titrated dosing, adjusted by a physician in real time based on your response
- On-site medical staff with the ability to intervene immediately if needed
- Structured preparation and integration support to help members process the experience and connect insights to daily life
This level of oversight matters. As one clinician told Fox News in response to the executive order: “It’s not like prescribing someone a Tylenol and sending them home. These medicines require medical oversight.”
At-home ketamine options, typically sublingual lozenges or nasal sprays, do not offer the same precision or safety. Without continuous monitoring and the ability to adjust dosing in real time, the experience is less predictable. This is why Nushama uses IV administration exclusively, which gives clinicians the most control over the therapeutic experience.
What happens next
The executive order sets several things in motion. The FDA will issue national priority vouchers for three psychedelic compounds, compressing review timelines. The first human ibogaine trials on U.S. soil will begin. And $50 million in federal funds will flow to state programs developing psychedelic therapies.
None of this means ibogaine or psilocybin will be prescribed at your local pharmacy anytime soon. Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, told the AP: “If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others.”
Federal policy is moving toward expanded access to psychedelic-assisted therapies, with a particular focus on veterans and people whose conditions have not responded to conventional treatments. How quickly that movement becomes responsible, accessible care depends on the safety protocols, clinical evidence, and trained providers behind it.
For people who need help now, the wait for ibogaine or psilocybin approval does not have to mean waiting for treatment. Ketamine-assisted therapy, delivered with medical supervision and integration support, is available today. If you or someone you care about is living with treatment-resistant depression, PTSD, or anxiety, speaking with our care team is a place to start.
FAQs
Is ketamine included in Trump’s psychedelic executive order?
- Yes. The April 18, 2026 order names ketamine alongside ibogaine, psilocybin, LSD, and MDMA. However, ketamine is already a Schedule III substance and legally available by prescription, so the order’s most significant impact is on compounds like ibogaine and psilocybin that are currently Schedule I.
When will ibogaine or psilocybin be available for treatment in the U.S.?
- There is no firm timeline. The executive order fast-tracks FDA review and opens a Right to Try pathway, but ibogaine and psilocybin still need to complete clinical trials and regulatory review. The FDA is planning the first human ibogaine trials on U.S. soil, and national priority vouchers may compress review timelines, but full approval could still take years.
Is ibogaine safe?
- Ibogaine carries documented cardiac risks, including dangerous heart rhythms, and has been linked to more than 30 deaths in the medical literature, most in unregulated settings. A 2024 Stanford study found that combining ibogaine with intravenous magnesium may reduce cardiac risk, but that study involved only 30 participants. More research is needed before its safety profile is fully understood.
How is ketamine different from ibogaine and psilocybin?
- Ketamine is a Schedule III substance, meaning it is already legal and available by prescription. It was FDA-approved as an anesthetic in 1970 and has been used off-label for depression, anxiety, and PTSD. Ibogaine and psilocybin are Schedule I substances with no current FDA approval for psychiatric use. Ketamine also works through NMDA receptor pathways rather than serotonin pathways, which means people do not need to taper off most antidepressants before starting treatment.
What does “off-label” mean for ketamine?
- Off-label prescribing means a licensed clinician prescribes a medication for a condition other than what it was originally approved for. The FDA approved ketamine as an anesthetic, but clinicians legally prescribe it for depression, anxiety, PTSD, and other conditions based on growing clinical evidence. Off-label use is a standard, accepted practice across all fields of medicine.
Can I access ketamine therapy for PTSD right now?
- Yes. IV ketamine therapy for PTSD is available today at clinics like Nushama that offer medically supervised, individually titrated treatment with preparation and integration support. You do not need to wait for the executive order’s provisions to take effect. Book a consultation to learn whether ketamine-assisted therapy may be appropriate for your situation.